U.S., Oct. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07220603) titled 'An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)' on Oct. 22.
Brief Summary: The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Myotonic Dystrophy 1
Intervention:
DRUG: PGN-EDODM1
Administered by intravenous (IV) infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: PepGen Inc
Published by HT Digital Content Services with permission from Health Daily Digest....